This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. **(Currently Amended)** A compound of Formula I:

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula:

$$-L-M-L^1,$$

wherein L is phenyl, optionally substituted by halogen, up to per-halo, and Wn, where n is 0-3;

wherein each W is independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to perhaloalkyl [[,]] and C_1-C_3 alkoxy ~~, C_1-C_3 haloalkoxy up to perhaloalkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, CN, and NO_2~~;

L^1 is selected from ~~phenyl,~~ pyridinyl ~~and pyrimidinyl~~ substituted by $-C(O)R_x$, and

optionally substituted with 1-3 additional substituents independently selected from the group consisting of R^7 and halogen ~~, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano and nitro~~;

wherein R_x is NR_aR_b and R_a and R_b are

A) independently

a) hydrogen,

b) C_1-C_{10} alkyl,

~~c) C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O~~

~~d)~~ c) C_6 aryl,

~~e)~~ d) pyridinyl ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl,~~

~~pyridinyl pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

~~f)~~ e) substituted C_{1-10} alkyl,

~~g) substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O,~~

~~h)~~ f) substituted C_6 aryl,

~~i)~~ g) substituted pyridinyl ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl~~,

~~j)~~ h) ~~-phenylpiperazine(pyridyl)~~ -phenylpiperazine(pyridinyl),

i) -phenylmorpholinyl,

j) -ethylmorpholinyl,

k) -ethylpiperidyl,

l) -methyl pyrrolidinyl,

m) -methyl tetrahydrofuryl,

or

~~k)~~ n) $-C_2H_4NH$(phenyl);

where when R_a and R_b are a substituted group, they are substituted by

a) halogen up to per halo,

b) hydroxy,

c) $-N(CH_3)_2$,

d) C_1-C_{10} alkyl,

e) C_1-C_{10} alkoxy,

~~f) C_{3-12} cycloalkyl, having 1-3 heteroatoms selected from O, N and S,~~

~~g)~~ f) halosubstituted C_{1-6} alkyl, or

~~h)~~ g) $-OSi(Pr\text{-}i)_3$; or

B) R_a and R_b together form piperazine or a substituted piperazine with substituents selected from the group consisting of

a) halogen,

b) hydroxy,

c) C_{1-10} alkyl,

~~d) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,~~

~~e)~~ d) pyridinyl ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

~~h)~~ e) C_{1-10} alkoxy,

~~g)~~ f) C_6 aryl,

~~h)~~ g) ~~halo substituted C_{1-6} alkyl up to per halo alkyl,~~

~~i)~~ h) halo substituted C_6 aryl ~~up to per halo aryl~~, and

~~j)~~ i) N-(4-acetylphenyl);

~~k) halo substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, and~~

~~l) halo substituted hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

~~or~~

~~C) one of R_a or R_b is C(O) bound to the moiety L^+ to form an isoindoline-1,3-dione structure, a C_1-divalent alkylene group or a substituted C_1-divalent alkylene group bound to the moiety L^+ to form a 1-oxo-isoindoline structure,~~

~~wherein the substituents of the substituted C_1-divalent alkylene group are selected from the group consisting of~~

~~a) halogen,~~

~~b) hydroxy,~~

~~c) C_{1-10} alkyl,~~

~~d) C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N,~~

~~e) hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl and pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

~~f) C_{1-10} alkoxy,~~

~~g) C_6 aryl,~~

~~h) halo substituted C_{1-6} alkyl up to per halo alkyl,~~

~~i) halo substituted C_6 aryl up to per halo aryl,~~

~~j) halo substituted C_3-C_{12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, and~~

~~k) halo substituted hetaryl up to per halo heteroaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl pyrimidinyl benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

M is selected from the group consisting of oxygen and sulfur;

and

B is

phenyl, ~~optionally~~ substituted with 1-3 substituents independently selected from the group consisting of halogen and R^7, ~~OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, and nitro;~~

and R^7 is ~~each R^7 and $R^{7'}$ is independently~~

~~(a) hydrogen,~~

~~(b)~~ (a) C_1-C_6 linear [[,]] or branched ~~, or cyclic~~ alkyl, optionally substituted with 1-3 halogen substituents; ~~substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, up to perhalo substituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy and halogen;~~ or

~~(c)~~ (b) C_1-C_6 linear or branched [[,]] alkoxy ~~, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched~~

~~alkyl, up to perhalo substituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy and halogen~~.

2. (Canceled)

3. (Previously Presented) A compound as in claim 1 wherein M is oxygen .

4. (Previously Presented) A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

5. (Canceled)

6. (Currently Amended) A compound of claim 1 wherein B of Formula I is phenyl, ~~optionally~~ substituted with 1-3 substituents independently selected from the group consisting of ~~R^7, OR^7, halogen, cyano, and nitro~~ halogen, C_1-C_6 alkoxy or up to per halo substituted C_1-C_6 alkyl

7. (Currently Amended) A compound of claim ~~1~~ 3 wherein B of Formula I is phenyl, substituted with 1-3 substituents independently selected from the group consisting of halogen, ~~; or~~

~~C_1-C_{10} alkyl,~~

C_1-~~C_{10}~~ C_6 alkoxy, or

substituted C_1-~~C_{10}~~ C_6 alkyl, substituted by one or more halogen substituents ~~independently selected from the group consisting of halogen , up to per halo , or~~

~~substituted C_1-C_{10} alkoxy, substituted by one or more substituents independently selected from the group consisting of halogen, up to per halo~~.

8. (Currently Amended) A compound of claim ~~6~~ 4 wherein B of Formula I is phenyl, substituted 1 to 3 times by 1 or more substituents selected from the group consisting

of halogen, ~~C_1-C_6 alkyl,~~ C_1-C_6 alkoxy[[,]] or up to per halo substituted C_1-C_6 alkyl ~~, or up to per halo substituted C_1-C_6 alkoxy~~.

9. (Previously Presented) A compound of claim 1, wherein L is phenyl, optionally substituted by halogen up to perhalo.

10. (Currently amended) A compound of claim ~~8~~ 1, wherein L is

~~(i)~~ phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of halogen ~~, C_1-C_6 alkyl, C_1-C_6 halosubstituted alkyl~~ and C_1-~~C_6~~ C_3 alkoxy.

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Currently Amended) A compound of claim ~~14~~, 4, wherein M is -O- .

19. (Currently Amended) A compound of claim ~~15~~, 8 wherein M is -O-.

20. (Currently Amended) A compound of claim ~~16~~, 9 wherein M is -O-.

21. (Currently Amended) A compound of claim ~~17~~, 10 wherein M is -O- .

22. (Currently Amended) A compound of claim ~~12~~ 1 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-~~C_{10}~~ C_6 alkyl, ~~up to per halo substituted C_1-C_{10} alkyl, CN, OH,~~ halogen[[,]] and C_1-~~C_{10}~~ C_6 alkoxy ~~and up to per halo substituted C_1-C_{10} alkoxy~~.

23. (Currently Amended) A compound of claim ~~14~~ 3 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-~~C_{10}~~ C_6 alkyl, ~~up to per halo substituted C_1-C_{10} alkyl, CN, OH,~~ halogen[[,]] and C_1-~~C_{10}~~ C_6 alkoxy ~~and up to per halo substituted C_1-C_{10} alkoxy~~.

24. (Currently Amended) A compound of claim ~~15~~ 18 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-~~C_{10}~~ C_6 alkyl, ~~up to per halo substituted C_1-C_{10} alkyl, CN, OH,~~ halogen[[,]] and C_1-~~C_{10}~~ C_6 alkoxy ~~and up to per halo substituted C_1-C_{10} alkoxy~~.

25. (Currently Amended) A compound of claim ~~16~~ 19 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-~~C_{10}~~ C_6 alkyl, ~~up to per halo substituted C_1-C_{10} alkyl, CN, OH,~~ halogen[[,]] and C_1-~~C_{10}~~ C_6 alkoxy ~~and up to per halo substituted C_1-C_{10} alkoxy~~.

26. (Currently Amended) A compound of claim ~~17~~ 20 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-~~C_{10}~~ C_6 alkyl, ~~up to per halo substituted C_1-C_{10} alkyl, CN, OH,~~ halogen[[,]] and C_1-~~C_{10}~~ C_6 alkoxy ~~and up to per halo substituted C_1-C_{10} alkoxy~~.

27. (Currently Amended) A compound of claim 21 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1-~~C_{10}~~ C_6 alkyl, ~~up to per halo substituted C_1-C_{10} alkyl, CN, OH,~~ halogen[[,]] and C_1-~~C_{10}~~ C_6 alkoxy ~~and up to per halo substituted C_1-C_{10} alkoxy~~.

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32.(Canceled)

33. (Currently Amended) A compound of claim ~~13~~ 3 wherein ~~L^1 is substituted by $C(O)R_x$, wherein R_x is NR_aR_b, and~~ R_a and R_b are independently hydrogen or C_1-C_6 alkyl.

34. (Currently Amended) A compound of claim ~~14~~ 18 wherein ~~L^1 is substituted by $C(O)R_x$, wherein R_x is NR_aR_b, and~~ R_a and R_b are independently hydrogen or C_1-C_6 alkyl.

35. (Currently Amended) A compound of claim ~~15~~ 19 wherein ~~L^1 is substituted by $C(O)R_x$, wherein R_x is NR_aR_b, and~~ R_a and R_b are independently hydrogen or C_1-C_6 alkyl.

36. (Currently Amended) A compound of claim ~~16~~ 20 wherein ~~L^1 is substituted by $C(O)R_x$, wherein R_x is NR_aR_b, and~~ R_a and R_b are independently hydrogen or C_1-C_6 alkyl.

37. (Currently Amended) A compound of claim ~~17~~ 21 wherein ~~L^1 is substituted by $C(O)R_x$, wherein R_x is NR_aR_b, and~~ R_a and R_b are independently hydrogen or C_1-C_6 alkyl.

38. (Currently Amended) A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-M-L^1, wherein

L is ~~(i)~~ phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to perhalo, C_1-C_3 alkoxy and halogen ~~, C_1-C_3 haloalkoxy up to per haloalkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, and nitro~~;

L^1 is ~~selected from a~~

~~(i) phenyl, substituted by $-C(O)R_x$, and optionally substituted by 1-3 substituents which are independently methyl or halogen; or~~

~~(ii)~~ pyridinyl, substituted by $-C(O)R_x$ ~~, and optionally substituted with 1-3 substituents which are independently methyl or halogen~~;

wherein R_x is NR_aR_b and R_a and R_b are independently

hydrogen,

C_1-C_{10} alkyl,

C_6 aryl,

pyridinyl, ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

substituted $C_{1\text{-}10}$ alkyl,

~~substituted $C_{3\text{-}10}$ cycloalkyl, having 0-3 heteroatoms selected from N, S and O,~~

substituted C_6 aryl, or

substituted pyridinyl, ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

where R_a and R_b are a substituted group, they are substituted by halogen up to per halo[[,]] ; and

M is selected from the group consisting of oxygen and sulfur

and

B is ~~selected from the group consisting of:~~

~~(i)~~ phenyl, ~~optionally~~ substituted with 1-3 substituents independently selected from the group consisting of R^7 [[,]] and halogen ~~, cyano and nitro~~;

and R^7 is

~~each R^7 and $R^{7'}$ is independently~~

~~(a) hydrogen,~~

~~(b)~~ (a) C_1-C_6 linear[[,]] or branched ~~, or cyclic~~ alkyl, optionally substituted with 1-3 halogen substituents ~~independently selected from the group consisting of C_1-C_5 linear or branched alkyl, up to perhalo substituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, and hydroxy and halogen~~; or

~~(c)~~ (b) C_1-C_6 linear or branched [[,]] alkoxy ~~, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, up to perhalo substituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy and halogen~~.

39. (Currently Amended) A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-M-L^1,

L is phenyl,

M is -O-,

L^1 is pyridinyl substituted by -$C(O)R_x$,

wherein R_x is NR_aR_b and R_a and R_b are independently

hydrogen,

C_1-C_{10} alkyl,

~~C_{3-10} cycloalkyl,~~

C_6 aryl,

pyridinyl, ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

substituted C_{1-10} alkyl,

~~substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O,~~

substituted C_6 aryl, or

substituted pyridinyl ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl,~~

~~benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

where R_a and R_b are a substituted group, they are substituted by halogen up to per halo, and

B is a phenyl group substituted by trifluoromethyl or tert-butyl, and optionally additional substituents selected from the group consisting of halogen up to per halo, and ~~W~~ W_n where n is 0-3, and each W is independently selected from the group consisting of

C_1-C_{10} alkyl,

C_1-C_{10} alkoxy,

~~C_3-C_{10} cycloalkyl,~~

C_6 aryl,

pyridinyl, ~~hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl and pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,~~

and substituted C_1-C_{10} alkyl, substituted by one or more substituents independently selected from the group consisting of ~~OR^7 and~~ halogen up to per halo ~~, wherein R^7 is hydrogen or C_1-C_{10} alkyl; and~~

~~substituted C_1-C_{10} alkoxy, substituted by one or more substituents independently selected from the group consisting of OR^7 and halogen up to per halo, wherein R^7 is hydrogen or C_1-C_{10} alkyl;~~

~~substituted C_3-C_{10} cycloalkyl, substituted by one or more substituents independently selected from the group consisting of OR^7 and halogen up to per halo, wherein R^7 is hydrogen or C_1-C_{10} alkyl;~~

~~substituted C_6 aryl, substituted by one or more substituents independently selected from the group consisting of OR^7 and halogen up to per halo, wherein R^7 is hydrogen or C_1-C_{10} alkyl;~~

~~substituted hetaryl selected from furyl, thienyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, triazolyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl,~~

~~benzoxadiazolyl and quinazolinyl, substituted by one or more substituents independently selected from the group consisting of OR^7 and halogen up to per halo, wherein R^7 is hydrogen or C_1-C_{10} alkyl;~~

~~$-CN$,~~

~~$-CO_2R^7$;~~

~~$-C(O)NR^7R^7$;~~

~~$-C(O)R^7$;~~

~~$-NO_2$;~~

~~$-OR^7$;~~

~~$-NR^7R^7$~~

~~$-NR^7C(O)OR^7$ and~~

~~$-NR^7C(O)R^7$, wherein R^7 is hydrogen, or C_1-C_{10} alkyl.~~

40. (Previously Presented) A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

41. (Canceled)

42. (Previously Presented) A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

43. (Canceled)

44. (Currently amended) A compound as in claim 38 wherein substituents for B, are selected from the group consisting of ~~C_1-C_6 alkyl~~ up to per halo substituted C_1-C_6 alkyl and ~~, CN, OH,~~ halogen ~~, C_1-C_6 alkoxy and up to per halo substituted C_1-C_6 alkoxy~~.

45. (Currently Amended) A compound as in claim 39 wherein the optional substituents for B are selected from the group consisting of ~~C_1-C_6 alkyl~~ up to per halo substituted C_1-C_6 alkyl ~~, CN, OH, C_1-C_6 alkoxy and up to per halo substituted C_1-C_6 alkoxy~~ and halogen.

46. (Canceled)

47. (Canceled)

48. (Canceled)

49. (Canceled)

50. (Previously Presented) A pharmaceutically acceptable salt of a compound of formula I of claim 1 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

51. (Cancelled)

52. (Canceled)

53. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 38 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

54. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 39 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

55. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

56. (Canceled)

57. (Canceled)

58. (Previously Presented) A pharmaceutical composition comprising a compound of formula I of claim 38 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

59. (Previously Presented) A pharmaceutical composition comprising a compound of formula I of claim 39 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

60. (Canceled)

61. (Cancelled)

62. (Currently Amended) A method for inhibiting the enzyme raf kinase in a human or animal ~~the treatment of a cancerous cell growth mediated by raf kinase~~, comprising administering a compound of Formula I of claim 1 to said mammal.

63. (Canceled)

64. (Currently Amended) A method for inhibiting the enzyme raf kinase in a human or animal ~~the treatment of a cancerous cell growth mediated by raf kinase~~, comprising administering a compound of Formula I of claim 38 to said mammal.

65. (Currently Amended) A method for inhibiting the enzyme raf kinase in a human or animal ~~the treatment of a cancerous cell growth mediated by raf kinase~~, comprising administering a compound of Formula I of claim 39 to said mammal.

66. (Canceled)

67. (Canceled)

68. (Previously Presented) A compound of claim 1 wherein the optional substituents on L^1 are selected from the group consisting of methyl, triflouromethyl, methoxy, Cl and F.

69. (Currently Amended) A compound of claim 1 wherein the ~~optional~~ substituents of B and L are independently selected from the group consisting of methyl, triflouromethyl, ~~ethyl, n-propyl, n-butyl, n-pentyl,~~ tert-butyl, ~~sec-butyl, isobutyl,~~ methoxy, ~~ethoxy, propoxy,~~ Cl, and F.

70. (Previously Presented) A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of formula I of claim 1 or a pharmaceutically acceptable salt of a compound of formula I and a physiologically acceptable carrier.

71. (Currently Amended) A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula: -L-M-L^1,

wherein L is phenyl, optionally substituted with substituents independently selected from the group consisting of halogen, C_1-C_5 alkyl, C_1-C_5 alkyl substituted by halogen and C_1-C_5 alkoxy;

L^1 is ~~comprises a substituted cyclic moiety selected from the group consisting of:~~

~~(i) phenyl, substituted with -C(O)NR^aR^b and optionally substituted with one or two substituents selected from the group consisting of R^7, OR^7 and halogen wherein R^7 is hydrogen, C_1-C_5 alkyl or C_1-C_5 alkyl substituted by halogen, and~~

~~(ii)~~ pyridinyl, substituted with -C(O)NR^aR^b ~~and optionally substituted with one or two substituents selected from the group consisting of R^7, OR^7 and halogen, wherein R^7 is hydrogen, C_1-C_5 alkyl or C_1-C_5 alkyl substituted by halogen,~~

wherein R^a and R^b independently are

a) hydrogen[[,]] or

b) C_1-C_5 alkyl, ~~optionally substituted by CF_3, C_1-C_3 alkoxy, hydroxy, halogen, or di (C_1-C_4-alkyl)amino,~~

M is oxygen ~~or sulfur~~;

B is phenyl, substituted by tert-butyl or trifluoromethyl and optionally substituted with additional substituents independently selected from the group consisting of

a) halogen [[;]] ,

b) C_1-C_5 alkyl ~~, optionally~~ substituted by halogen ~~or OR^7 wherein R^7 is hydrogen or C_1-C_5 alkyl;~~ or

c) C_1-C_4 alkoxy, ~~optionally substituted by halogen;~~

~~d) phenyl or O-phenyl, optionally substituted by C(O)NHCH$_3$, C_1-C_5-alkyl, halogen or OR^7 wherein R^7 is hydrogen or C_1-C_5 alkyl; or~~

~~e) pyrrolyl or pyridinyl, optionally substituted by C_1-C_5 alkyl, halogen or OR^7 wherein R^7 is hydrogen or C_1-C_5 alkyl.~~

72. (Previously Presented) A pharmaceutical composition for the treatment of a cancerous cell growth as in claim 71 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

73. (Canceled)
74. (Canceled)
75. (Canceled)
76. (Canceled)
77. (Canceled)
78. (Canceled)
79. (Canceled)
80. (Canceled)
81. (Canceled)
82. (Canceled)
83. (Canceled)
84. (Canceled)
86. (Canceled)
87. (Canceled)
88. (Canceled)
89. (Canceled)